Follow us on Twitter
twitter icon@FreshPatents


Antagonist patents

      

This page is updated frequently with new Antagonist-related patent applications.




 Methods of selectively treating asthma using il-13 antagonists patent thumbnailMethods of selectively treating asthma using il-13 antagonists
The disclosure is directed to novel predictive methods and personalized therapies for treating asthma. Specifically, this disclosure relates to methods of treating a patient having asthma by selectively administering an il-13 antagonist, on the basis of that patient being genetically predisposed to have a favorable response to treatment with the il-13 antagonist.

 Truncated trk b and trk c antagonists and uses thereof patent thumbnailTruncated trk b and trk c antagonists and uses thereof
Disclosed herein are compositions, methods, vectors, and kits comprising an antagonist of a truncated trkc or a truncated trkb. Also described herein are methods of diagnosing, treating and/or preventing a neurodegenerative disease or condition or a symptomatic or pre-symptomatic condition with alterations to synapses associated with an elevated expression level of a truncated trkc or truncated trkb isoform..

 Treatment using truncated trk b and trk c antagonists patent thumbnailTreatment using truncated trk b and trk c antagonists
Disclosed herein are methods, compositions, vectors, and kits comprising an antagonist of a truncated trkc or a truncated trkb. Also described herein are methods of treating and/or preventing an otic disease or condition associated with an elevated expression level of a truncated trkc or truncated trkb isoform..
Otonomy, Inc.


 Methods of improving or accelerating physical recovery after surgery for hip fracture patent thumbnailMethods of improving or accelerating physical recovery after surgery for hip fracture
The disclosure relates to uses and regimens for accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an actrii receptor binding molecule, an actrii receptor antibody, such as the bimagrumab antibody.. .
Novartis Ag


 Saa-domain-specific antibodies and peptide antagonists and use thereof to treat inflammatory diseases patent thumbnailSaa-domain-specific antibodies and peptide antagonists and use thereof to treat inflammatory diseases
Isolated saa peptides, fusion proteins and compositions comprising such are provided as are domain-specific saa antibodies. Methods of treating sepsis and endotoxemia are also provided..
The Feinstein Institue For Medical Research


 (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof patent thumbnail(+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
The present invention provides (+)-morphinans comprising toll-like receptor 9 (tlr9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain..
Mallinckrodt Llc


 Novel chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor mediated disorders and chiral synthesis thereof patent thumbnailNovel chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor mediated disorders and chiral synthesis thereof
The present invention relates to novel compounds of formula i and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using n-sp3 protective groups.

 Pyrimidine compound and medical use  thereof patent thumbnailPyrimidine compound and medical use thereof
Wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like.

 Nk 1 antagonists patent thumbnailNk 1 antagonists
Or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by nk1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.. .

 5-ht2b antagonists patent thumbnail5-ht2b antagonists
And related methods for treating a person having a disorder characterized by undesirable 5-ht2b receptor signaling, such as migraine, irritable bowel syndrome (ibs), pulmonary arterial hypertension (pah), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (gi) tract disorders.. .

Neurogenic brain-derived neurotrophic factor peptides

Five tetra peptides corresponding to different active regions of brain derived neurotrophic factor (bdnf) that are neurotrophic and can modulate bdnf signaling in a partial agonist/antagonist way. The peptides offer a therapeutic approach to neural pathologies where bdnf levels are dysregulated..
Research Foundation For Mental Hygiene, Inc.

Methods and compositions for treatment of peripheral neuropathies

A composition for therapy of a peripheral neuropathy disorder in a subject in need thereof. The composition comprises an effective amount of an agent selected from a group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, a muscarinic receptor antagonist, and combinations thereof, and a pharmacologically acceptable carrier and/or an excipient.
University Of Manitoba

Piperidinone carboxamide azaindane cgrp receptor antagonists

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists ofcgrp receptors and useful in the treatment or prevention of diseases in which the cgrp is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which cgrp is involved..
Merck Sharp & Dohme Corp.

Compositions and methods for prophylaxis and treatment of addictions

The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (pparγ) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a pparγ agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse.
Omeros Corporation

Treatment of autoimmune disorders and infections using antagonists of sgk1 activity

The present invention provides novel methods for treating th2-mediated immune disorders and enhancing th1-mediated immune responses in a subject comprising administering to the subject, a pharmaceutical composition comprising a serum-glucocorticoid regulated kinase 1 (sgk1) inhibitor and a pharmaceutically acceptable carrier. Methods for treating a wide range of autoimmune diseases are also taught.
The Johns Hopkins University

Solid dispersion comprising an orexin receptor antagonist

A solid dispersion comprising suvorexant or a salt thereof in amorphous form and at least one pharmaceutically acceptable matrix compound, wherein the matrix compound is (i) a polymer and wherein the solid dispersion contains the suvorexant or salt thereof in an 5 amount of at least 50 weight-% based on the combined weight of the suvorexant or salt thereof and the at least one matrix compound, or (ii) a silicon-based inorganic adsorbent.. .
Sandoz Ag

Method of treating t cell mediated disorders

A method of treating a t-cell mediated disorders in a tissue includes administering to the tissue of the subject a therapeutically effective amount of a complement antagonist that substantially reduces t-cell differentiation or t-cell inflammatory cytokine generation.. .
Case Western Reserve University

Compositions comprising rank/rankl antagonists and related compounds for treating pain

Disclosed herein are methods of treating pain using comprising rank/rankl antagonists.. .
Antecip Bioventures Ii Llc

Methods of inhibiting tumor growth by antagonizing il-6 receptor

The present invention provides methods for inhibiting or attenuating tumor growth in a subject by administering an il-6 antagonist to the subject. In certain embodiments, the methods of the invention are used to inhibit the growth of an anti-vegf-resistant tumor in a subject.
Regeneron Pharmaceuticals, Inc.

Preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient

A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising an interleukin-6 (il-6) antagonist, for example an antibody directed against il-6 receptor, an antibody directed against il-6, an antibody directed against gp130, and the like.. .
Chugai Seiyaku Kabushiki Kaisha

Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation

Compounds are provided that act as potent antagonists of the ccr2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of ccr2-mediated diseases and as controls in assays for the identification of ccr2 antagonists..
Chemocentryx, Inc.

Fast dissociating dopamine 2 receptor antagonists

The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects..

Combination therapy for the treatment of autoimmune diseases

The present invention pertains to compounds and their combination for use in the prevention or therapy of a subject suffering from an autoimmune disease such as diabetes type 1. Provided are antagonists of t-cells that are used in combination with antagonists of the cytokine cxcl10, sequentially or concomitantly, in a subject suffering from an autoimmune disease, in particular diabetes type 1..
Fraunhofer-gesellschaft Zur Förderung Der Angewandten Forschung E.v.

Compositions and methods for increasing insulin sensitivity

Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin.
Orexigen Therapeutics, Inc.

Methods for the treatment of depression and anxiety

Methods of treating a depressive disorder or an anxiety disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising ac-nle4-c[asp5-his6-(nme)d-nal(2′)7-arg8-trp9-(nme)lys10]-nh2 (peptide 9), in a pharmaceutically acceptable carrier is administered to the subject.
The Arizona Board Of Regents On Behalf Of The University Of Arizona

Methods for the treatment of central nervous system (cns) disorders and mood disorders

Methods of treating a central nervous system (cns) disorder or mood disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising a melanocortin 5 receptor (mc5r) peptide ligand in a pharmaceutically acceptable carrier is administered to the subject.
The Arizona Board Of Regents On Behalf Of The University Of Arizona

Process for the identification of compounds for treating cancer

Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the mda-5 protein or increase noxa protein levels and to trigger autophagy.
FundaciÓn Centro Nacional De Investigaciones OncolÓgicas Carlos Iii

Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration

Disclosed herein are methods of treating disorders of the retina (e.g., macular degeneration, retinitis pigmentosa, etc.) comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound (for example, an antipsychotic drug) that blocks or diminishes agonist-mediated responses upon binding to either dopamine d2-like receptors or serotonin 5-ht2 receptors.. .
United States Government As Represented By The Department Of Veterans Affairs

Treatment of impaired cognitive flexibility with trkb receptor antagonists

The cognitive flexibility of a subject may be improved by administering a therapeutically effective amount of a trkb receptor antagonist to the subject in need thereof. The trkb receptor antagonist compound may be administered in a pharmaceutical dosage form..
The General Hospital Corporation

Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Crf1 receptor antagonists have the potential to directly inhibit acth release in patients with cah and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.. .
Neurocrine Biosciences, Inc.

Opioid agonist/opioid antagonist/acetaminophen combinations

The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome)..
Purdue Pharma L.p.

Inos-inhibitory compositions and their use as breast cancer therapeutics

Disclosed are methods for treating one or more mammalian cancers, and in particular, methods for treating human breast cancer employing one or more inos pathway-inhibitory compounds, either alone, or in combination with one or more selected antihypertensive agents, including calcium channel antagonists, either alone, and further in combination with one or more conventional chemotherapeutic or anti-cancer regimens. Also disclosed are particular therapeutic formulations including these compositions, and methods for their use in treating refractory, metastatic, and relapsed cancers, and for managing or reversing treatment resistance in human triple-negative breast cancers in particular..
The Methodist Hospital

Compositions and methods for modulating and redirecting immune responses

Provided herein are methods of modulating and redirecting an immune response. Compositions and methods for killing targeted cells in a cell population are also provided wherein, a cell population containing target cells expressing a target associated antigen and t cells are contacted with 1, 2, or more immune checkpoint antagonists and a multispecific t cell-redirecting agent that specifically binds the target associated antigen expressed on the target cells and specifically binds a t cell surface antigen..
Duke University

Cd86 antagonist multi-target binding proteins

This disclosure provides a multi-specific fusion protein composed of a cd86 antagonist binding domain and another binding domain that is an il-10 agonist, an hla-g agonist, an hgf agonist, an il-35 agonist, a pd-1 agonist, a btla agonist, a light antagonist, a gitrl antagonist or a cd40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains.
Aptevo Research And Development Llc

Growth hormone receptor agonists

We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists.. .
Asterion Limited

Superagonists and antagonists of interleukin-2

Novel human interleukin-2 (il-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed.
The Board Of Trustees Of The Leland Stanford Junior University, Office Of The General Counsel

Use of arylalkanolamines as sigma-1 receptor antagonists

The present invention relates to the use of arylalkanolamine compounds with sigma-1 receptor antagonist activity. In particular, the said arylalkanolamine compounds are useful in the treatment of conditions selected from the abuse of psychotropic substances such as cocaine or amphetamines, pain and cancer..
Università Degli Studi Di Pavia

Tin-117m somatostatin receptor binding compounds and methods

Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic.
Serene, Llc

Compositions and methods of treating t cell mediated disorder

A method of generating a cd4+foxp3+ treg cell, the method includes administering at least one complement antagonist to a naive cd4+ t cell at an amount effective to substantially inhibits c3a receptor (c3ar) and/or c5a receptor (c5ar) signal transduction in the cd4+ t cell, induce tgf-β1 expression of the cd4+ t cell, and induce differentiation of the of the naive cd4+ t cell into a cd4+foxp3+ treg cell.. .
Case Western Reserve University

Compositions and methods for administering galectin antagonists

The invention provides methods for the treatment of diseases and conditions relating to galectin 3 using a galectin-3 inhibitor, such as a modified pectin (e.g., gcs-100). Also described are methods for conjoint therapy, and methods for assessing and/or monitoring the effects of a galectin-3 inhibitor, e.g., to adapt the dosing regimen of the inhibitor during therapy..
La Jolla Pharmaceutical Company

Use of nk-1 receptor antagonists for treating hypomagnesemia, neurogenic inflammation, and cardiac dysfunction associated with egfr-blocking drugs

The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of egfr blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by egfr blocking drugs, by administering an nk-1 receptor antagonist..
The George Washington University

Abuse-resistant controlled-release opioid dosage form

Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally.
Purdue Pharma L.p.

Abuse-resistant controlled-release opioid dosage form

Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally.
Purdue Pharma L.p.

Method for inhibiting tumor metastasis

A leukotriene c4 and d4 antagonist is used to inhibit tumor metastasis by acting to inhibit tumor cell adhesion to endothelial cells, therby preventing tumor cell extravasation.. .
Inflammation Research Center Company Ltd.

Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies

The invention provides compositions and methods for treating her2-postitive cancers. The method comprising administering a pd-1 axis binding antagonist and an antibody that targets her2..
Genentech, Inc.

Spiro-oxazolones

The present invention provides spiro-oxazolones, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag..
Hoffmann-la Roche Inc.

Substituted thiazole or oxazole p2x7 receptor antagonists

The present invention refers to novel substituted thiazole and oxazole compounds of formula (i) having p2x7 receptor (p2x7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with p2x7 receptor activity in animals, in particular humans..
Axxam S.p.a.

Farnesoid x receptor antagonists

Provided herein are farnesoid x receptor (fxr) antagonists having the structure of formula (i), and pharmaceutical compositions comprising the compound of formula (i) and a pharmaceutically acceptable excipient. Also provided are methods of antagonizing fxr, and methods of treating metabolic disease in a subject in need thereof, comprising administering an effective amount of the fxr antagonists of formula (i) to a subject..
City Of Hope

Plant nutrient composition for synergistically increasing flavors and improving textures of fruits and fruit vegetables and method therefor

A plant nutrient composition of the present invention can produce high-quality fruits or fruit vegetables which cause substantially no chemical damage, have no antagonistic action of each component in crops, synergistically increase inherent flavors of fruits through interactions of nitrogen and calcium, and improve textures, by performing foliage spray through a specific range of weight ratio of total nitrogen and water-soluble calcium, the spray concentration, and the spray amount when fruits or fruit vegetables are cultivated.. .
Jahngryu Industries.,ltd

Pegylated growth hormone antagonists

A composition that is a human growth hormone receptor antagonist comprising human growth hormone receptor antagonist g120k, wherein at least one amino acid of human growth hormone receptor antagonist g120k has been mutated to cysteine; and a polytethylene glycol molecule (peg) conjugated to each cysteine residue in the human growth hormone receptor antagonist g120k mutant.. .

Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders

Provided herein, for example, are methods generally relating to the expansion and/or regeneration of central nervous system (cns) cells, such as nerve cells, astrocytes and oligodendrocytes, using an activator of cereblon (crbn), such as an inhibitor of a crbn substrate or downstream protein. Also provided herein, for example, are methods related to the expansion of neural stem cells, neural progenitor cells, or neural precursor cells and/or differentiation of these cells into cns cells using a brd7 antagonist, ikaros antagonist, or crbn activator.
Celgene Corporation

Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders

The invention relates to methods for preventing stress-associated disorders. These disorders may be treated with a serotonin 2c receptor (5-ht2cr) antagonist prior to, during, or following a stress-related event.
Massachusetts Institute Of Technology

Compositions for affecting weight loss

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (mc3-r) or a melanocortin 4 receptor (mc4-r) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-msh activity..
Orexigen Therapeutics, Inc.

Peripheral opioid receptor antagonists and uses thereof

Wherein x−, r1, and r2 are as defined herein, and compositions thereof.. .

Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (lamas)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (rao), summer pasture associated obstructive pulmonary disease (spaopd), and inflammatory airway disease (iad) in animals, preferably equines such as horses..
Boehringer Ingelheim Vetmedica Gmbh

Method of treating or inhibiting the development of brain inflammation and sepsis

A leukotriene c4 and d4 antagonist is used to treat or inhibit brain inflammation and sepsis by acting to inhibit increased capillary permeability and white blood cell extravasation. Potential candidate compounds can be screened in a non-human mammal before or after administration of an inflammation inducing agent into the subarachnoid space by determining their ability to inhibit increased capillary permeability and white blood cell extravasation..
Inflammation Research Center Company Ltd.



Antagonist topics:
  • Antagonist
  • Recurrence
  • Proliferative Disorder
  • Proliferative
  • Antibodies
  • Progesterone
  • Dicyclomine
  • Scopolamine
  • Extracellular
  • Pharmaceutically Acceptable Salt
  • Metalloprotein
  • Nucleic Acids
  • Polynucleotide
  • Nucleic Acid
  • Monoclonal


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.4961

    file did exist - 2752

    1 - 1 - 59